(AGENPARL) – mar 17 ottobre 2023 Lund, Sweden, 17 October 2023. Hansa Biopharma, “Hansa” (Nasdaq Stockholm:
HNSA), a pioneer in enzyme technology for rare immunological conditions, today
announced results from an extended pooled analysis using data from the 17
-HMedIdeS-14 study,[1] an international long-term follow-up study of patients
who have received a kidney transplant following desensitization with imlifidase,
showing sustained positive outcomes out to 5 years in the majority of highly
sensitized patients who received an imlifidase-enabled kidney transplant. After
5 years, the patient survival rate was 90% (three deaths occurring between six
months and one year, and no deaths occurring between one and five years) and
graft survival (death censored) was 82%, in line with outcomes seen at 3-years
post-transplant.[2 ]At five years, mean estimated glomerular filtration rate
(eGFR) was 50 mL/min/m[2]. eGFR is a measure of how well the kidneys are working
in the body.[3 ]
Søren Tulstrup, President and CEO, Hansa Biopharma said, “The results from this
study confirm the important role imlifidase plays in desensitization in kidney
transplantation and further supports the clinical benefit of enabling HLA
-incompatible kidney transplantation with imlifidase. Conditionally approved and
marketed in Europe as Idefirix[®] (imlifidase), we believe it is a paradigm
shifting treatment in kidney transplantation – one that will positively impact
patient outcomes and ensure that highly sensitized patients waiting for a kidney
have access to transplantation.”
The 17-HMedIdeS-14 study included patients who consented to long-term follow-up
and had previously received an imlifidase-enabled transplant in Hansa’s phase 2
studies. The 5-year extended pooled analysis is a continuation of the analysis
at 3-years of crossmatch positive only patients published in the American
Journal of Transplantation. Hansa is continuing to analyze the data from 17
-HMedIdeS-14 along with the extended pooled analysis and plans to share further
data in 2024.
Tomas Lorant, MD PhD, Associate Professor of Transplant Surgery, Uppsala
University Hospital, Uppsala, Sweden, said, “It is encouraging to see the
outcome of patients five years out from an incompatible kidney transplant and
its consistency with the 3-year data that was published in 2021. Despite the
high-risk immunological profile of these patients, we see stable long-term
outcomes both on graft survival and patient survival, not different from what we
otherwise see in compatible kidney transplantation.”[4  ]
Stanley Jordan, MD, FASN, FAST,  Professor of Pediatrics & Medicine and Director
of Nephrology & Transplant Immunology, Cedars-Sinai Medical Center, Los Angeles,
CA, said, “These results reinforce the case for HLA-incompatible transplantation
following desensitization with imlifidase being a viable and concrete option for
patients on the waitlist who are highly sensitized and predicted to have low
likelihood to access a compatible kidney offer, removing their dependency on
dialysis treatment.”
Imlifidase is a promising new strategy for desensitization of transplant
patients with donor-specific anti-HLA (Human Leukocyte Antigens) antibodies
(DSAs).[11] Highly sensitized patients have high levels of preformed antibodies
that can damage the transplant.[12] Once they inactivated with imlifidase, there
is a window of opportunity for the transplant to take place. By the time the
body starts to synthesize new IgG, the patient will be receiving post-transplant
immunosuppressive therapy to reduce the risk of organ rejection.
— ENDS —
Contacts for more information:
Klaus Sindahl, VP Head of Investor Relations
Stephanie Kenney, VP Global Corporate Affairs
Imlifidase
Imlifidase is an antibody-cleaving enzyme originating from Streptococcus
pyogenes that specifically targets and cleaves immunoglobulin G (IgG) antibodies
and inhibits IgG-mediated immune response.[10] It has a rapid onset of action,
cleaving IgG-antibodies and inhibiting their activity within hours after
administration.
Imlifidase is conditionally approved in Europe and marketed under the trade name
Idefirix[®] for the desensitization treatment of highly sensitized adult kidney
transplant patients with a positive crossmatch against an available deceased
donor. The use of imlifidaseshould be reserved for patients who are unlikely to
be transplanted under the available kidney allocation system, including
prioritization programs for highly sensitized patients.[10] Imlifidase was
reviewed as part of the European Medicines Agency’s (EMA) Priority Medicines
(PRIME) program, which supports medicines that may offer a major therapeutic
advantage over existing treatments or benefit patients without treatment
options.[10]
HMedIdes Clinical Trial Program
17-HMedIdeS-14 is part of the HMedIdeS clinical program for imlifidase. The
program includes four global phase 2 trials (13-HMedIdeS-02, 13-HMedIdeS-03, 14
-HMedIdeS-04 and 15-HMedIdeS-06), one US open-label phase 3 trial (ConfIdeS), a
long-term follow up study (17-HMedIdeS-14) and a post-authorization efficacy and
safety study in Europe (PAES).
About kidney failure and highly sensitized patients
Kidney disease can progress to kidney failure or End-Stage Renal Disease (ESRD),
identified when a patient’s kidney function is less than 15%.[14] ESRD poses a
significant health burden, affecting nearly 2.5 million patients
worldwide.[15] A kidney transplant is the treatment of choice for suitable
patients with ESRD because it offers improved survival and quality of life
benefits, and has cost savings compared to long-term dialysis. There are
approximately 80,000 kidney patients on transplant waiting lists across the
European Union.[17]
Highly sensitized patients have pre-formed antibodies called donor specific
antibodies (DSAs) with a broad reactivity against human leukocyte antigens
(HLAs), which can cause tissue damage and potentially transplant rejection.[4]
The presence of DSAs means that highly sensitized patients tend to have limited
or no access to transplant, as finding a compatible donor organ can be
particularly challenging.[6,7] The complexity of their immunological profile
means that highly sensitized patients spend longer time than average on
transplant waiting lists, with evidence showing that this longer time waiting
for a suitable donor relates to an increased mortality risk.[6,7] Across the
U.S. and Europe, highly sensitized patients comprise around 10-15% of the total
of patients on transplant waiting lists.[8,9]
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a
mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. Hansa has developed
a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which
has been shown to enable kidney transplantation in highly sensitized patients.
Hansa has a rich and expanding research and development program based on the
Company’s proprietary IgG-cleaving enzyme technology platform, to address
serious unmet medical needs in transplantation, autoimmune diseases, gene
therapy and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations
in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the
ticker HNSA. Find out more at http://www.hansabiopharma.com.
Full product information can be accessed via the initial Summary of Product
Characteristics found here (https://www.hansabiopharma.com/mediatoolkit/).
References
ggFilters=status:com
2. Kjellman C et al. Am J Transplantation 2021 Dec;21(12):3907-3918.
3. American Kidney Fund. All About the Kidneys. https://www.kidneyfund.org/all
-about-kidneys/tests/blood-test
-egfr#:~:text=eGFR%20(estimated%20glomerular%20filtration%20rate)%20is%20a%20meas
ure%20of%20how,well%20your%20kidneys%20are%20working. Accessed October 2023.
4. Poggio E et al. Am J Transplant. 2021 Aug;21(8):2824-2832.
5. Eurostam Report (A Europe-wide strategy to enhance transplantation of highly
sensitized patients on the basis of acceptable HLA mismatches.) Available
at https://cordis.europa.eu/project/id/305385/reporting.
6. Redfield R, et al. Nephrol Dial Transplant 2016; 31:1746-1753
7. Lonze BE, et al. Ann Surg 2018; 268(3):488-496
8. EDQM. (2020). International figures on donation and Transplantation 2019
9. SRTR Database and individual assessments of allocation systems
10. European Medicines Agency. Idefirix[®] summary of product characteristics.
Available at: https://www.ema.europa.eu/en/documents/product
-information/idefirix-epar-product-information_en.pdf.
11. Jordan SC, et al. N Engl J Med 2017; 377(5):442-453.
12. Manook M, et al.  Lancet 2017; 389(10070):727-734.
14. Lorant T, et al. Am J Transplant 2018;18(11):2752-2762.
15. Jordan SC, et al. Transplantation October 21 2020 – volume online first
issue
16. NIH (2018). What is kidney failure? Available at:
https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/what
-is-kidney-failure.
17. Newsletter Transplant 2020. pp 58-60.
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/2Qjsnz8Yfp2LuquKHDJxFGC6xqDb2EHZrRpkwJKfhVBGBU1YB7tSg5bh44Y4Ek5JuF1BvRCgwVvSMBz4YfSs7bZs43koFNsH9nq4EADhCRkDyV.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/2Qjsnz8Yfp2LuquKHDJxFGC6xqDb2EHZrRpkwJKfhVBGBU1YB7tSg5bh44Y4Ek5JuF1BvRCgwVvSMBz4YfSs7bZs43koFNsH9nq4EADhCRkDyV.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden